Skip to main content
Assets
AstraZeneca logo
AZN.LSE
AstraZeneca
Health Care · Pharmaceuticals

British-Swedish multinational pharmaceutical and biotechnology company developing treatments for cancer, cardiovascular, and respiratory diseases.

HQ: United KingdomListed: United Kingdom

AI Forecasts

Compare independent AI Advisor forecasts, ratings, scenarios, risks, configurations, sources, and step-by-step prediction paths for AstraZeneca.

AstraZeneca plc (AZN.LSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 3 July 2026Deep analysis 5 July 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Elon Musk AI advisor icon

Elon Musk AI

The Visionary FrameworkAI Thinker

Price-adjusted rating

Strong Buy

5-Year Return Est.

+134.2%

Includes 0.02% annual net dividend contribution

1. Investment Thesis — Base Case

I strongly believe AZN is a exhibiting Paradigm Shifter characteristics, aggressively attacking the physical limits of biological engineering. The Base Case anticipates a volatile but inexorable climb.

  • We are looking at a 10x as precision oncology shifts cancer from terminal to manageable.
  • The physics are sound: in-silico simulation mathematically reduces thermodynamic waste in the pipeline.
  • is accelerating, with R&D spend compounding intelligently at $14.2B to force the S-curve upward.
  • is robust, meaning AZN has achieved and requires no dilutive capital to reach the future.
  • While regulatory gravity and Warsh rate hikes will introduce aggressive local corrections, the intrinsic accumulation of biological data constitutes an insurmountable moat. The implied capitalization remains realistic when viewed through the lens of a sovereign-level biotech .

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.5.94K12.3K18.65K25.01K31.36KJun 2021Dec 2023Jul 2026Dec 2028Jul 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (GBX)
Observed price2021-06-298,675
Observed price2021-07-038,765
Observed price2021-07-238,417
Observed price2021-08-088,232
Observed price2021-08-208,708
Observed price2021-08-248,589
Observed price2021-09-178,063
Observed price2021-09-258,618
Observed price2021-10-119,003
Observed price2021-10-198,739
Observed price2021-11-049,443
Observed price2021-11-168,602
Observed price2021-12-108,193
Observed price2021-12-148,228
Observed price2021-12-308,673
Observed price2022-01-198,785
Observed price2022-02-048,356
Observed price2022-02-088,356
Observed price2022-02-289,167
Observed price2022-03-088,886
Observed price2022-04-0110,135
Observed price2022-04-0510,302
Observed price2022-04-0910,824
Observed price2022-05-0310,684
Observed price2022-05-1110,026
Observed price2022-06-169,760
Observed price2022-06-2410,776
Observed price2022-07-1011,104
Observed price2022-07-2210,766
Observed price2022-08-1110,506
Observed price2022-08-1911,250
Observed price2022-08-2711,241
Observed price2022-09-1610,119
Observed price2022-09-2810,076
Observed price2022-10-149,818
Observed price2022-10-229,719
Observed price2022-11-0310,682
Observed price2022-11-1510,800
Observed price2022-12-0911,354
Observed price2022-12-1711,234
Observed price2023-01-0611,717
Observed price2023-01-1011,685
Observed price2023-02-0310,333
Observed price2023-02-0710,666
Observed price2023-02-1911,496
Observed price2023-03-1110,695
Observed price2023-03-3111,192
Observed price2023-04-0411,432
Observed price2023-04-2412,267
Observed price2023-05-2212,028
Observed price2023-05-2611,613
Observed price2023-06-0711,754
Observed price2023-06-2311,422
Observed price2023-06-2711,190
Observed price2023-07-0910,096
Observed price2023-08-1011,162
Observed price2023-08-1810,658
Observed price2023-09-0310,683
Observed price2023-09-1510,793
Observed price2023-09-1910,839
Observed price2023-09-2711,085
Observed price2023-10-1710,792
Observed price2023-11-0610,240
Observed price2023-11-1810,243
Observed price2023-11-2610,026
Observed price2023-12-1610,226
Observed price2024-01-0510,758
Observed price2024-01-0910,902
Observed price2024-02-0210,360
Observed price2024-02-0610,534
Observed price2024-02-109,662
Observed price2024-03-0510,112
Observed price2024-03-2910,696
Observed price2024-04-0210,604
Observed price2024-04-2611,988
Observed price2024-04-3012,062
Observed price2024-05-2412,329
Observed price2024-05-2812,028
Observed price2024-06-0512,516
Observed price2024-06-2512,550
Observed price2024-07-0712,000
Observed price2024-07-2312,190
Observed price2024-08-1613,046
Observed price2024-09-0113,276
Observed price2024-09-1312,042
Observed price2024-09-1711,936
Observed price2024-09-2911,621
Observed price2024-10-1511,980
Observed price2024-11-089,790
Observed price2024-11-169,990
Observed price2024-12-0210,746
Observed price2024-12-1010,620
Observed price2024-12-1810,375
Observed price2025-01-1510,648
Observed price2025-01-3111,344
Observed price2025-02-0411,030
Observed price2025-02-2811,968
Observed price2025-03-0412,064
Observed price2025-03-2811,416
Observed price2025-04-0111,366
Observed price2025-04-099,667
Observed price2025-05-0310,645
Observed price2025-05-1510,176
Observed price2025-06-1211,030
Observed price2025-06-2010,392
Observed price2025-06-2810,132
Observed price2025-07-1410,662
Observed price2025-07-2210,352
Observed price2025-08-1511,592
Observed price2025-08-1911,782
Observed price2025-09-0412,150
Observed price2025-09-2811,055
Observed price2025-10-1012,886
Observed price2025-10-2212,485
Observed price2025-11-0712,907
Observed price2025-11-1113,322
Observed price2025-11-2714,061
Observed price2025-12-1313,460
Observed price2025-12-2913,737
Observed price2026-01-1414,346
Observed price2026-01-2213,560
Observed price2026-02-0313,816
Observed price2026-02-2715,542
Observed price2026-03-0314,932
Observed price2026-03-2313,742
Observed price2026-04-0415,283
Observed price2026-04-2413,956
Observed price2026-05-0613,322
Observed price2026-05-2213,997
Observed price2026-05-2613,960
Observed price2026-06-1513,200
Observed price2026-07-0514,219
Observed price2026-07-1712,594
Observed price2026-07-2913,134
Observed price2026-08-1411,460
Observed price2026-08-2612,234
Observed price2026-09-1111,708
Observed price2026-09-1512,116
Observed price2026-09-1812,500
Published advisor forecast2026-07-0314,456
Published advisor forecast2026-10-0315,034
Published advisor forecast2027-01-0315,485
Published advisor forecast2027-04-0315,795
Published advisor forecast2027-07-0316,427
Published advisor forecast2027-10-0316,098
Published advisor forecast2028-01-0316,903
Published advisor forecast2028-04-0317,579
Published advisor forecast2028-07-0318,634
Published advisor forecast2028-10-0319,193
Published advisor forecast2029-01-0319,961
Published advisor forecast2029-04-0320,959
Published advisor forecast2029-07-0321,588
Published advisor forecast2029-10-0322,019
Published advisor forecast2030-01-0323,120
Published advisor forecast2030-04-0324,045
Published advisor forecast2030-07-0325,488
Published advisor forecast2030-10-0326,252
Published advisor forecast2031-01-0327,303
Published advisor forecast2031-04-0328,122
Published advisor forecast2031-07-0329,246

2. Scenarios & Signals

Bull case

If AZN triggers its in-silico autonomy milestone, this is an explosive Paradigm Shifter setup.

  • R&D attrition rates collapse, driving an immediate 30 percent expansion.
  • Universal CRISPR payload delivery is validated, opening up the entire monogenic disease .
  • Market recognizes AZN not as legacy pharma, but as a frontier biological tech platform.
  • Escapes traditional P/E ceilings entirely, demanding software-level multiples.

Bear case

If the physics of AI simulation fail to cross the in-vivo barrier, AZN becomes a Narrative Trap.

  • Computational failures in Phase III shatter the efficiency thesis, forcing reliance on legacy trial costs.
  • Draconian sovereign completely neuter the upside of the existing oncology portfolio.
  • The massive $14.2B R&D budget evaporates into operating losses rather than compounding assets.
  • Valuation compresses painfully as the crowd abandons the innovation premium.

Current crowd narrative

The crowd views AstraZeneca as a high-quality, defensive, legacy pharmaceutical that provides a safe harbor from the Hormuz macro shock and tech-volatility. Sell-side research is obsessively anchored to next quarter's oncology sales and timelines. The prevailing consensus treats AZN's as mere corporate jargon and fundamentally prices the stock on trailing multiples and rather than technological optionality.

Alpha-gap assessment

The lies in the physics of R&D scaling. The market misprices AZN as a chemical synthesizer governed by the traditional 10-year, $2 billion drug development cycle. A first-principles analysis reveals they are actively transforming into an information-technology company reprogramming corrupted biological code. By dismissing AZN's computationally compressed R&D cycles, the market ignores a mathematically inevitable inflection point in and pipeline velocity. They are missing the transition from '' to 'adaptive survivor' and ultimately 'future builder'.

Convergence catalyst

The closes violently when AZN publishes Phase III clinical data for a primary oncology or rare-disease asset that was entirely designed and simulated in-silico, proving an unprecedented timeline compression. This will force Wall Street to re-rate the entire pipeline's net present value.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus